SUANFARMA CDMO: A Flexible and Strategic API Partner, interview with David Blanco

SUANFARMA provides Contract Development and Manufacturing (CDMO) services for fermentation and chemical synthesis projects – both generic and innovator.
The company offers a ‘One Stop Shop’ service helping customers to achieve success in the development, scaling, manufacturing, and commercialization of APIs.

David Blanco Industrial Business Development & CDMO Director, explains the services that they offer to customers.

“SUANFARMA is more than just a CDMO, we are a real strategic partner for success in achieving customers’ final goals. We have a flexible mindset and full transparency with customers, providing them with tailored solutions to meet specific needs.”

“We specialise helping pharmaceutical, biotech and healthcare companies by delivering fully integrated services that compress timelines to market. We provide global solutions that enable customers to achieve their objectives with high quality at affordable cost, including full regulatory support for FDA and EMA.”
The pharma industry needs CDMO partners to be flexible with manufacturing due to changing market dynamics, says David.

“Our flexibility and transparency are highly valued by our customers, we adapt to changes that arise during the project accommodate, batch size requirements and guarantee the capacity on time as per the business plan.”

David explains that a key differentiator for SUANFARMA is offering a single European manufacturing plant can combine GMP, industrial processes of fermentation, purification and chemical synthesis services.

“Centralisation of commercial manufacturing processes at a single site simplifies the supply chain and thus achieves highly attractive costs, minimises risk and optimises time.”

The sustainability footprint is also improved as the site including access for full waste recycling, use of green power, and the use of green chemistry to reduce environmentally harmful processes.
Innovative solution for wastewater treatment
SUANFARMA’s ground-breaking Pharmaceutical Wastewater Treatment Project has led to them being nominated alongside their partner e-Watts have been nominated for the 2023 CPHI Awards in the Sustainability category.

“It’s the world’s first large scale installation that treats industrial volumes with a flow rate of up to 250 m3 per hour.” says David.
“Our innovative solution is an improvement of existing wastewater treatment technologies that often rely on dangerous chemicals or incineration, which can be harmful to the environment.”

“We use electro-oxidation which doesn’t require the use of dangerous chemicals and can remove non-biodegradable compounds and pollutants from volumes of wastewater, making it a much more efficient and eco friendly option.”

In addition, the plant generates green hydrogen as a by-product of the electrolysis process, which can be used as an energy source to reduce the facility’s dependency on external energy sources.
Read the full article here